FDA
-
-
-
-
-
-
-
Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Ultragenyx Pharma (RARE)
-
-
-
-
-
-
-
Ultragenyx begins rolling FDA submission for GSDIa gene therapy
-
-
-
-
-
-
-
Ultragenyx stock falls after FDA issues complete response letter for gene therapy
-
-
-
-
-
-
-
Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update
-
-
-
-
-
-
-
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones
-
-
-
-
-
-
-
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

